Relay Therapeutics Hopes ‘Safety First’ Approach Will Pay Off For Targeted Breast Cancer Drug
Share Price Tanks After Virtually No Response To Therapy
Executive Summary
Investors have deserted Relay after RLY-2608 failed to produce any clear response in breast cancer patients, but it maintains underlying data represent proof-of-concept for a more targeted and less toxic competitor to Novartis's Piqray.